Companies in the cannabis industry need leaders to help navigate a complex and continually evolving regulatory and legal landscape.
|
Resources
Our attorneys help interested companies remain current on the shifting landscape of the cannabis industry by regularly publishing industry insights.
 |
Blog | Cannabis Legal Highlights |
|
|
|
||
 |
Podcast | The 411 on 420 |
|
|
|
||
 |
Resource | American Bar Association Treatise: Cannabis Law In addition to longstanding questions of federal legality and tension with state law, cannabis companies face a broad range of issues that require sophisticated legal guidance. For example, legal questions may involve litigation, real estate, advertising, or food and drug law. |
|
|
These questions are especially challenging given the breakneck pace with which cannabis policy and law has developed within changing and conflicting federal, state, and local systems. Failure to navigate these concerns deftly and thoughtfully jeopardizes financial growth, not to mention business survival. Until now, there has been no single reference to guide cannabis attorneys along the full continuum of potential legal needs challenging the industry. In conjunction with the ABA, our attorneys have written a new treatise that fills the gap from a sophisticated perspective by flagging key issues in more than a dozen practice areas, and covering the impact of cannabis policy from federal and Canadian enforcement and regulatory agencies. By mapping these diverse concerns, this treatise helps provide useful guardrails for in-house and outside counsel alike. The treatise was edited by Barak Cohen, chair of the Perkins Coie Cannabis Law Industry Group, with assistance from Michael Bleicher. |
||
Whitepapers
|
Standardizing Cannabis Lab Testing Nationally As the legal cannabis market continues to expand, and potential federal legalization and inevitable interstate commerce loom on the horizon, it is imperative that federal agencies address the discrepancies among state testing requirements and develop a standardized testing regime. Adoption of national standards will advance public health and safety goals while also facilitating interstate commerce of safe cannabis products. In this white paper, the National Cannabis Laboratory Council (NCLC) proposes a unified approach to testing based on both data from participating laboratories and scientifically recognized standards. There is a need to transition from a state variable testing program to a harmonized testing scheme to create a baseline for quality testing of cannabis products and allow for interstate commerce while the industry transitions to risk-based testing programs designed by the cultivators and manufacturers. The group further suggests setting national standards governing (1) standard test panels setting forth specific compounds to include in an analysis, (2) sampling requirements and testing methodologies, and (3) lab accreditation and proficiency testing requirements. |
|
Building New Foundations in the Cannabis Industry: Creating Gender Parity through Ownership, Leadership, Boards, Pay Equality, Branding, and Capital “Building New Foundations in the Cannabis Industry: Creating Gender Parity through Ownership, Leadership, Boards, Pay Equality, Branding, and Capital,” takes a hard look at gender parity in the U.S. cannabis industry. The research, data, personal stories, and case studies in this series demonstrate why gender parity is crucial to business success. Longtime industry partners and cannabis research leaders The Arcview Group and National Cannabis Industry Association (NCIA) champion equity, advocate for social justice, and help those affected by the war on drugs. Together, the two groups are honoring the inauguration of the first female vice president of the United States through a series of whitepapers written by a exceptional women. |
|
The Medicine of Cannabis: An Overview for Medical Professionals and Policymakers “The Medicine of Cannabis: An Overview for Medical Professionals and Policymakers” provides medical professionals and policymakers with an up-to-date, science-based perspective on the medicine of cannabis in the United States. It includes input from medical doctors, researchers, veterinarians, and policy experts, all committed to the development of a cannabis industry founded on scientific research, patient safety, and equitable access to safe products and clinical oversight. It includes a history of medical cannabis, an overview of the endocannabinoid system and the complex nature of the cannabis plant, and explores clinical uses as well as safety considerations. The paper also highlights the obstacles that currently hinder research and includes policy recommendations to remove those barriers and promote evidenced-based therapeutic cannabis access and use. Andrew Kline, senior counsel at Perkins Coie and the former Public Policy Director of NCIA, was one of the editors for this whitepaper. |
